Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung CancerAntonio Calles, Pasi A. Jänne, David M. Jackman et al.|Journal of Thoracic Oncology|2015Cited by 290
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II StudyGlenn J. Hanna, Jochen H. Lorch, Naifa L. Busaidy et al.|Clinical Cancer Research|2018Cited by 125
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Alfredo Addeo, Nir Peled et al.|Journal of Thoracic Oncology|2022Cited by 97
ROS-1 NSCLC therapy resistance mechanismMiguel García-Pardo, Antonio Calles|Precision Cancer Medicine|2021Cited by 17
Brief Report: Clinical Outcomes Using Plasma-Based Molecular Profiling to Guide Treatment Decisions in Patients With Advanced NSCLC and Limited Access to Broad Tissue TestingMiguel García-Pardo, Antonio Calles, Inmaculada Aparicio et al.|Clinical Lung Cancer|2023Cited by 4